



GB04101926



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 02 JUN 2004


WIPO. PC

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gershey*  
Dated 20 May 2004

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

The  
Patent  
Office



1/77

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

**Request for grant of a patent**

See the notes on the back of this form. You can also get explanatory leaflet from the Patent Office to help you fill in this form)

Your reference

T1627PV

12 MAY 2003

Patent application number  
(The Patent Office will fill in this part)

0310881.8

Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited  
Hertford Road, Hoddesdon  
Hertfordshire EN11 9BU  
United Kingdom

15 MAY 03 E806612-1 002639  
P01/7700 0.00-0310881.8

Patents ADP number (if you know it)

00597799001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

Title of the invention

Pharmaceutical formulation

Name of your agent (if you have one)

Dr. J. Thompson

Address for service" in the United Kingdom, which all correspondence should be sent including the postcode)

Merck & Co., Inc.  
European Patent Department  
Terlings Park  
Eastwick Road  
Harlow  
Essex CM20 2QR

4448791001

Patents ADP number (if you know it)

4392742002

If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number  
(if you know it)

Date of filing  
(day/month/year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day/month/year)

Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

any applicant named in part 3 is not an inventor, or there is an inventor who is not named as an applicant, or any named applicant is a corporate body. (note (d))

**Patents Form 1/77**

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 7

Claim(s) 0

Abstract 0

Drawing(s) 0

If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

I/We request the grant of a patent on the basis of this application.

Signature

Dr. J. Thompson

Date 12 May 2003

Name and daytime telephone number of person to contact in the United Kingdom.

Dr. J. Thompson

01279 440172

**Warning**

When an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You are informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or publication has been given, or any such direction has been revoked.

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

Write your answers in capital letters using black ink or you may type them.

If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

If you have answered 'Yes' Patents Form 7/77 will need to be filed.

Once you have filled in the form you must remember to sign and date it.

For details of the fee and ways to pay please contact the Patent Office.

## PHARMACEUTICAL FORMULATION

The present invention relates to a pharmaceutical composition comprising a combination of active ingredients. More particularly, the invention concerns a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor (hereinafter referred to as a "glycine/NMDA antagonist") in combination with a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.

Glycine/NMDA antagonists are well known from the art to be of benefit in the treatment of acute neurodegenerative disorders arising from events such as stroke, transient ischemic attack, peri-operative ischemia, global ischemia (following cardiac arrest), and traumatic head injury to the brain or spinal cord. In addition, glycine/NMDA antagonists may be of use in treating certain chronic neurological disorders such as senile dementia, Parkinson's disease and Alzheimer's disease. They may also have utility in conditions in which peripheral nerve function has been impaired, such as retinal and macular degeneration.

Glycine/NMDA antagonists have, moreover, been reported as being beneficial in treating epilepsy; anxiety; substance abuse and/or addiction, e.g. alcoholism; pain; hearing disorders, e.g. tinnitus; migraine; and psychiatric disorders such as schizophrenia. However, mechanism-based side effects, principally including nausea and vomiting, have been reported following administration of certain glycine/NMDA antagonists during clinical trials.

The neuropeptide receptors for substance P (SP; neurokinin-1; NK-1) are widely distributed throughout the mammalian nervous system (especially the brain and spinal ganglia), circulatory system and peripheral tissues (especially the duodenum and jejunum), and are involved in regulating a variety of diverse biological processes. These

include the sensory perception of olfaction, vision, audition and pain; movement control; gastric motility; vasodilation; salivation; and micturition.

5 Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. In addition to SP, the known mammalian tachykinins include neurokinin A and neurokinin B. The current nomenclature designates the receptors for substance P, neurokinin A and neurokinin B as neurokinin-1, neurokinin-10 2 and neurokinin-3 respectively.

Tachykinin neurokinin-1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, in particular SP. Examples of such conditions include disorders of the 15 central nervous system including anxiety, depression and psychosis. Recently, the tachykinin NK-1 receptor antagonist aprepitant [2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine] has been approved by the US Food and Drug Administration (FDA) for use in preventing the acute and 20 delayed nausea and vomiting associated with cancer chemotherapeutic agents, including high-dose cisplatin.

It has now been found that the co-administration of a glycine/NMDA antagonist in conjunction with a tachykinin NK-1 receptor antagonist provides beneficial results in the treatment of 25 neurodegeneration arising, in particular, from stroke or cerebral ischemia.

The present invention accordingly provides a method for the treatment of neurodegeneration which comprises administering to a patient in need of such treatment, either simultaneously, separately or sequentially, a combination of a glycine/NMDA antagonist and a 30 tachykinin NK-1 receptor antagonist.


The present invention also provides the use of a combination of a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist for the manufacture of a medicament for the treatment of neurodegeneration.

5 In another aspect, the present invention provides a pharmaceutical composition comprising a glycine/NMDA antagonist in association with a tachykinin NK-1 receptor antagonist.


In a further aspect, the present invention provides a product containing a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist as a combined preparation for simultaneous, separate or  
10 sequential use in the treatment of neurodegeneration.

In the normal practice of the invention, the glycine/NMDA antagonist and the tachykinin NK-1 receptor antagonist will usually be administered to a patient within a reasonable period of time, which will typically be up to about one hour apart. The compounds may be in the  
15 same pharmaceutical carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers and administered simultaneously, by mixing the materials just prior to administration. They may alternatively be in different dosage forms which can be taken simultaneously, or administered sequentially.

20 Typical glycine/NMDA antagonists of use in the present invention are, for example, described in EP-A-0481676. Preferred glycine/NMDA antagonists of use in this invention include UK-240,455 and UK-333,747, disclosed in WO 96/09295 [Example 80(d)] and WO 98/38186 (derived from WO 97/32873) respectively, the chemical structures of which are as  
25 follows:



UK-240,455



UK-333,747

The tachykinin NK-1 receptor antagonists of use in the present invention may be peptidal or non-peptidal in nature. However, the use of a non-peptidal tachykinin NK-1 receptor antagonist is preferred. In a preferred embodiment, the tachykinin NK-1 receptor antagonist is a CNS-penetrant tachykinin NK-1 receptor antagonist. In addition, for convenience the use of an orally active tachykinin NK-1 receptor antagonist is preferred. To facilitate dosing, it is also preferred that the tachykinin NK-1 receptor antagonist is a long acting tachykinin NK-1 receptor antagonist. An especially preferred class of tachykinin NK-1 receptor antagonists of use in the present invention comprises those compounds which are both orally active and long acting.

Tachykinin NK-1 receptor antagonists of use in the present invention are fully described, for example, in U.S. Patent Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926, 5,496,833 and 5,637,699; European Patent Publication Nos. EP 0 360 390, 0 394 989, 0 428 434, 0 429 366, 0 430 771, 0 436 334, 0 443 132, 0 482 539, 0 498 069, 0 499 313, 0 512 901, 0 512 902, 0 514 273, 0 514 274, 0 514 275, 0

514 276, 0 515 681, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456,  
 0 533 280, 0 536 817, 0 545 478, 0 558 156, 0 577 394, 0 585 913, 0 590  
 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535,  
 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 709 375, 0 709 376,  
 5 0 714 891, 0 723 959, 0 733 632 and 0 776 893; PCT International Patent  
 Publication Nos. WO 90/05525, 90/05729, 91/09844, 91/18899, 92/01688,  
 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677,  
 92/22569, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170,  
 93/06099, 93/09116, 93/10073, 93/14084, 93/14113, 93/18023, 93/19064,  
 10 93/21155, 93/21181, 93/23380, 93/24465, 94/00440, 94/01402, 94/02461,  
 94/02595, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843,  
 94/08997, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639,  
 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735,  
 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886,  
 15 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382,  
 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 95/22525, 95/23798,  
 95/26338, 95/28418, 95/30674, 95/30687, 95/33744, 96/05181, 96/05193,  
 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197,  
 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385,  
 20 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362,  
 97/18206, 97/19084, 97/19942, 97/21702 and 97/49710; and British Patent  
 Publication Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774,  
 2 292 144, 2 293 168, 2 293 169 and 2 302 689.

25 A preferred tachykinin NK-1 receptor antagonist of use in the  
 present invention is aprepitant (*supra*), disclosed in WO 95/16679.

In a preferred embodiment of the present invention, UK-240,455 or  
 UK 333,747 may be co-administered, as described herein, with aprepitant.

30 The pharmaceutical composition according to the present invention  
 may conveniently be adapted for administration orally, rectally or  
 parenterally. For oral administration, the formulation may be presented  
 in the form of tablets, pills, capsules, powders or granules; for parenteral

administration, sterile parenteral solutions or suspensions may conveniently be utilised; and for rectal administration, the formulation may conveniently be in the form of suppositories. Suitably, the pharmaceutical compositions in accordance with the invention may be presented in the form of a kit of parts adapted for simultaneous, separate or sequential administration.

The compositions may be formulated by conventional methods well known in the pharmaceutical art, for example as described in *Remington: The Science and Practice of Pharmacy*, Mack Publishing Company, 19th Edition, 1995.

For administration in combination, the glycine/NMDA antagonist and the tachykinin NK-1 receptor antagonist may be presented in a ratio which is consistent with the manifestation of the desired effect. In particular, the molar ratio of the glycine/NMDA antagonist to the tachykinin NK-1 receptor antagonist will suitably be approximately 1 to 1. Preferably, this ratio will be between 0.001 to 1 and 1000 to 1, and especially from 0.01:1 to 100:1.

For co-administration with a tachykinin NK-1 receptor antagonist in the treatment of neurodegeneration, the glycine/NMDA antagonist may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg, and especially about 0.05 to 10 mg/kg. For co-administration with a glycine/NMDA antagonist in the treatment of neurodegeneration, the tachykinin NK-1 receptor antagonist may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg and especially about 0.05 to 10 mg/kg. The active ingredients will typically be co-administered on a regimen of 1 to 4 times per day.

The following non-limiting Examples serve to illustrate the present invention.

# EXAMPLES 1 TO 4

## Tablet Preparation

5      Tablets containing UK-240,455 and aprepitant, or UK-333,747 and aprepitant, were prepared as follows:

	<u>Example 1</u>	<u>Example 2</u>
UK-240,455	5.0 mg	10.0 mg
Aprepitant	10.0 mg	10.0 mg
Microcrystalline cellulose	42.0 mg	39.5 mg
Modified food corn starch	42.0 mg	39.5 mg
Magnesium stearate	1.0 mg	1.0 mg

	<u>Example 3</u>	<u>Example 4</u>
UK-333,747	5.0 mg	10.0 mg
Aprepitant	10.0 mg	10.0 mg
Microcrystalline cellulose	42.0 mg	39.5 mg
Modified food corn starch	42.0 mg	39.5 mg
Magnesium stearate	1.0 mg	1.0 mg

10      All of the active ingredients, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and magnesium stearate. The resulting granulation is then compressed into tablets.